Press Release biotechnology

Ambrosia Biosciences Announces $100 Million Oversubscribed Series B Financing to Advance Novel Small Molecule Cardiometabolic Pipeline

Blue Owl Healthcare Opportunities Redmile Deep Track Capital BVF Partners Boulder Ventures Janus Henderson Investors Samsara BioCapital Ambrosia Biosciences Inc.
Press ReleaseMarch 31, 2026
Blue Owl Healthcare Opportunities

Ambrosia Biosciences Inc. has secured $100 million in an oversubscribed Series B financing to support the clinical development of its oral small molecule GLP-1 candidate and other cardiometabolic programs.

Related articles

Press ReleaseSeptember 16, 2026
ASSA ABLOY

ASSA ABLOY acquires PACLOCK in the US

September 16, 2026
Press ReleaseSeptember 16, 2026
MySize

MySize Announces $2.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

September 16, 2026
Press ReleaseSeptember 16, 2026
Xpansiv

Xpansiv to Acquire Formbay, Australia's AI-Enabled Renewable Energy Certificate and Compliance Technology Platform

September 16, 2026
← Back to all articles

Generated by Olivia 6